Skip to main content
Premium Trial:

Request an Annual Quote

Andrew von Eschenbach, Lester Crawford, Douglas Throckmorton, Walter Narajowski, Gustavo Salem


Andrew von Eschenbach has been named acting commissioner of the US Food and Drug Administration following the resignation of former commissioner Lester Crawford last week.

Von Eschenbach has been director of the National Cancer Institute, part of the National Institutes of Health, since January 2002. Before that, he worked as a doctor and executive at the M D Anderson Cancer Center in Houston. Von Eschenbach has said that he intends to act as both head of the FDA and director of NCI.

The appointment ends the tenure of Crawford who resigned last Friday.

Crawford, a veterinarian and expert on food safety, was named deputy commissioner of the agency in early 2002 before his tenure as acting commissioner began last year.

In a message to colleagues, Crawford cited his age — 67 — as a factor in his decision to step aside.

Douglas Throckmorton has been named deputy director of the Center for Drug Evaluation and Research by the FDA. Throckmorton joined the FDA in 1997 and has been acting deputy director of CDER since May 2004.

Before joining the FDA, Throckmorton practiced medicine and held academic appointments at the Medical College of Georgia and the VA Medical Center in Augusta, Ga.

Walter Narajowski has been named president and CEO of Pathways Diagnostics, the assay development company said this week. He will also join the firm's board of directors.

Narajowski was formerly the vice president and general manager of Focus Diagnostics' infectious disease reference lab. Prior to Focus, Mr. Narajowski spent over 20 years at Abbott Laboratories, where he was most recently vice president and general manager of critical care products and vice president and general manager of the infusion pump business.

Narajowski holds an MS in bioengineering from the University of Utah and a BSc in electrical engineering from Illinois Institute of Technology.

Assay Designs has appointed Gustavo Salem as its new president and CEO, the Ann Arbor, Mich.-based biotech firm said last week.

Prior to joining Assay Designs, Salem held a variety of positions at Bio-Rad Laboratories, including division manager of protein separations and business unit manager for biomaterials. Prior to this, he held a series of sales and marketing positions at PerSeptive Biosystems, Beckman Instruments, and Amersham.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.